| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 190.94 | 10.6% | 31.1% |
| Total Income | 195.10 | 10.8% | 23.6% |
| Expenditure | 153.61 | 12.0% | 37.8% |
| PBT | 41.49 | 6.5% | 10.6% |
| Net Profit | 30.93 | 12.0% | 5.2% |
| OPM | 37.85% | 0.56pp | 1.77pp |
| NPM | 15.85% | 4.11pp | 4.81pp |
| EPS | 4.79 | 13.4% | 5.2% |
Record revenue growth masking profit margin compression amid capex absorption
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
EBITDA margin delivered 37.9% vs guidance 32-35% (beat). PAT margin 15.8% vs 16.4% claimed (miss); profit growth guidance not met. Track record on capex delivery solid (facility on time, Sep 2026).
Cautiously Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Azad is executing a high-capex infrastructure build with strong revenue growth (+31% YoY, ₹190.9 Cr) and EBITDA leverage (37.9% margin), but near-term profitability is being crushed by depreciation, interest (+₹3.8 Cr YoY), and manpower costs (+₹17.8 Cr YoY). PAT declined 5.2% YoY despite 31% revenue growth—a red flag. The long-term narrative is compelling (₹1,300 Cr ARR by FY28, ₹6,500 Cr order book, OEM qualifications unlocking), but earnings recovery delayed to FY28. Near-term holds carry the cost of capital deployment; long-term holds the capex payoff.
₹190.9 Cr
Revenue · +31.1% YoY₹30.9 Cr
Reported PAT · −5.2% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Highest-ever quarterly revenue ₹187.8 Cr standalone; 31.6% YoY growth
METConsolidated ₹190.9 Cr; YoY +31.1%, nearly identical to claimed 31.6%
EBITDA ₹70.4 Cr grew 37.1% YoY; margin 37.5%
METConsolidated EBITDA margin 37.9%; well above claimed 37.5%; strong outperformance
PAT ₹30.8 Cr, margin 16.4%, profit stable sequentially
MISSPAT ₹30.9 Cr at 15.8% margin; declined 5.2% YoY and 12% QoQ (from Q1 ₹35.2 Cr)
H1 PAT grew 6.6% YoY to ₹67.2 Cr showing profit resilience
OVERSTATEDH1 growth 6.6% true, but Q2 alone shows -5.2% YoY decline; growth weighted by soft Q1
H1 revenue 29.3% growth ahead of 25% long-term guidance
METH1 ₹358 Cr confirmed; 29.3% growth validated; ahead of guidance
Capacity setup complete; 80% of expansion stabilized in Q1
MET44,800 sq m GE Vernova facility commissioned Sep 2026; production-ready; ramp begins Q3
Order book ₹6,500+ Cr; rolling contracts with multi-year visibility
METOrder book cited; 5-7 year rolling contract model; dependent on qualification completion
Earnings quality
What changed since the last call
Guidance reaffirmed; margin outperformance continues
Neutral25%+ long-term revenue growth maintained. 32-35% EBITDA margin guidance band; delivered 37.6% H1, 37.5% Q2 (well above). No numeric change; consistent outperformance on margins vs stated guidance.
PAT guidance not quantified; cost lag candidly disclosed
Downgradevs August call, management now explicit that PAT will lag EBITDA 'until cost base largely in place.' No FY27-28 net income target given; deflected with 'will update next quarter.' This is de facto withdrawal of specific profit guidance.
Capacity roadmap extended to ₹1,300 Cr ARR by FY28; multi-year visibility new
UpgradeNew explicit target: ₹1,300 Cr ARR by FY28 (vs ₹190.9 Cr Q2 = ₹760 Cr run rate now). Implies 1.7x growth from current to FY28, higher than historical 25%+ guidance. This is implicit upgrade in growth messaging, even if not stated as such.
Order book stable at ₹6,500 Cr; rolling contract model emphasized
NeutralOrder book unchanged from prior call (₹6,500 Cr). Clarity that it's 'rolling contracts' (5-7 year visibility), not one-time backlog. 44,800 sq m dedicated facilities demonstrate customer lock-in; no major new order disclosed Q2.
The Q&A
Analysts probed execution timelines (Gaurav Nagori on new facility land, Vikash Singh on FY28 targets), cash burn (Amit Dixit on Q4 stabilization), labor scaling (Kanwalpreet Singh on automation timeline), and qualification status (Alisha on delta qualification count). Management held firm on facility readiness and order visibility, but remained evasive on near-term profit targets ('I do not think...maybe next quarter I can update'). Tone confident on operations, defensive on earnings specifics.
Capex completion and cash burn — Amit Dixit, Goldman Sachs
AnsweredCapex largely complete; Q3 onwards ramp begins, Q4 cash flow expected to turn positive. H1 OCF -₹45.8 Cr, driven by inventory buildout; management flagged 'as throughput converts into revenue from quarter four, the inventory turn into receivable and then into the cash.'
New facility capacity and land needs — Gaurav Nagori, Avendus Capital
Partial1-2 buildings left at Tunki Bollaram; some customers want dedicated facilities there. Land 'well taken care of.' Beyond FY30 capex deferred to future calls; no clarity given.
FY28 revenue and long-term growth visibility — Vikash Singh, ICICI Securities
DodgedContracts with 25% growth visible. Rolls-Royce qualification 'will open new chapter.' But 'I do not think, maybe next quarter I can update you exactly what would be the range.' Deferred specificity.
Order book composition — Suraj Malu, Catamaran Ventures
AnsweredRolling contracts (5-7 year visibility). Not order backlog. Based on customer annual demands by product/segment. As capability expands (new qualifications), order book grows automatically.
Delta qualification status for engines — Alisha, TRUST Mutual Fund
PartialRolls-Royce 2 engines, Pratt & Whitney follow-on, Safran next. Qualifications 'almost done.' By FY 2030-31, energy/oil/gas ~55-60% of revenue, A&D ~16-17%. Testings ongoing; results expected soon.
Labor cost scaling and automation — Kanwalpreet Singh, Ambit Capital
AnsweredManpower hired ahead of revenue (capex phase). As revenue comes, cost per rupee falls. Targeting lean manufacturing and automation to reduce manpower dependency. Next 4-6 quarters show cost normalization.
Guidance
H2 FY27 revenue acceleration from new facilities; ₹1,300+ Cr ARR by FY28 end
MediumQ3 onwards throughput from GE Vernova, Mitsubishi lines; all plants fully ramped by Q2 FY28. ARR assumes customer qualification completion and 80%+ utilization.
H1 growth 29.3% YoY (vs 25%+ long-term guidance maintained)
HighDelivered ₹358 Cr H1, beat 25% guidance. Visible order book ₹6,500 Cr rolling 5-7 year contracts supports growth momentum.
Energy/Oil/Gas ramp Q4 onwards; 55-60% of revenue by FY 2030-31; A&D 16-17%
MediumDependent on facility utilization scaling and qualification timelines. Assumes Rolls-Royce, Safran, Pratt & Whitney qualify on schedule; delays would push revenue realization.
EBITDA margin 37.5%+ maintained (prior guidance 32-35% band)
HighH1 37.6%, Q2 37.5% both delivered well above band. Operating leverage from capacity utilization expected to sustain/improve margins as volumes grow.
PAT margin to improve as fixed costs absorbed and capacity utilizes
MediumCurrent margin 15.8% vs 17.2% H1 FY26. Depreciation INR21.8 Cr, interest INR12.2 Cr, manpower INR50.3 Cr will stabilize as debt-to-equity normalizes post-capex. Target: restore 17%+ by FY28.
New facilities capex largely complete; Treasury deployed and committed
High₹700 Cr QIP raised Sep 2025; ₹139.3 Cr spent on capex H1 FY27. Fixed assets INR1,169 Cr. Capex expected to moderate H2 onwards; maintenance capex only.
Risks the call surfaced
Qualification execution risk
HighQualifications described as 'almost done' but no firm completion dates provided. Rolls-Royce, Pratt & Whitney, Safran, GTRE each require test passes, revalidations, ramp-up phases (3-6 month buffers typical). Failure or delay strands new facility capacity.
Working capital management
HighInventory INR425 Cr (+INR98 Cr HoH), receivables INR402 Cr (+INR92 Cr). OCF H1 -INR45.8 Cr. CFO expects Q4 stabilization, but timing uncertain and macro risks (demand slowdown, customer payment delays) could extend cycle further.
Customer and export concentration
MediumExport revenue ₹147.8 Cr (88%), primarily to Mitsubishi, GE, Baker Hughes, Siemens. Top customer identities withheld ('few of the customers, I cannot name them'). GE Vernova facility is 6 dedicated customer lines; dedicated facilities create switching-cost lock-in but facility-customer pairing means single-customer loss = stranded asset.
Finance cost and leverage
MediumFinance costs INR12.2 Cr vs INR8.4 Cr YoY (+45%). Total debt ₹1.07 Cr (bank ₹536 Cr, term ₹340 Cr, WC ₹195.8 Cr as Sep 2026). Debt-to-equity 1.6x, debt-to-EBITDA (annualized) ~1.5x. If capex extends, interest rates rise, or demand slows, PAT pressure persists.
Geopolitical and defence dependency
MediumA&D segment (31.6% growth, ₹31.7 Cr Q2) dependent on Rolls-Royce (UK), Safran (France), Pratt & Whitney (US), and GTRE (India defence). US sanctions on Iran could reduce oil/gas engine demand. China competition in defence indigenization. Political shifts could disrupt qualification timelines.
Management
Score 7/10. Clear on operational metrics (facility size, customer names, order book). Vague on near-term profit targets ('will update next quarter'). Transparent on cost headwinds (manpower, interest, depreciation) but declined to quantify timing of recovery. Delivered capex on schedule (44,800 sq m GE Vernova commissioned Sep 2026, target achieved). Revenue growth targets hit consistently (25%+ maintained). PAT decline due to cost absorption, not operational miss. Manpower hired ahead of revenue (intentional capex phase investment).
1 · Q3 FY27 (Oct-Dec 2026)
Revenue ramp-up begins from GE Vernova, Mitsubishi dedicated lines; first aero engine airfoil shipments; working capital still elevated
2 · Q4 FY27 (Jan-Mar 2027)
All facilities operating; throughput conversion to cash; working capital cycle stabilization targeted; free cash flow inflection expected
3 · H1 FY28 (Apr-Sep 2027)
Rolls-Royce engine airfoil production revenue begins; Pratt & Whitney qualifications complete; additional OEM contracts signed; ₹1,300 Cr capacity edge closer to visible
Near-term holds carry the cost of capital deployment; long-term holds the capex payoff.
Record revenue, falling profit: Azad's capex trough gets real
Revenue up 31% and EBITDA margin at 37.9% — but net profit down 5.2% YoY. The quarter shows the cost of building out ₹1,300 crore of new capacity: depreciation, interest, and manpower are front-loaded, eating the operating gains.
₹190.9 Cr
31.1% YoY; beats 25% long-term guidance
37.9%
vs 32–35% guidance band; +150 bps YoY
₹30.9 Cr
-5.2% YoY; margin fell 160 bps to 15.8%
-₹45.8 Cr (H1)
Inventory +₹98 Cr, receivables +₹92 Cr; Q4 recovery flagged
The paradox of Azad's quarter: revenue soaring, EBITDA margin outperforming guidance — and profit falling. The 5.2% net-profit decline despite 31% revenue growth is the story. It is not an operational miss; it is capex absorption in motion.
Where the profit went
EBITDA grew 37.1% YoY to ₹70.4 Cr. Operating leverage is working. But the path from EBITDA to PAT is blocked by four cost lines, all front-loaded: depreciation ₹21.8 Cr (up ₹1.1 Cr YoY) from the GE Vernova facility commissioned September 2026; finance cost ₹12.2 Cr (up ₹3.8 Cr, +45% YoY) as debt funded the capex; manpower ₹50.3 Cr (up ₹17.8 Cr, +54%) teams hired ahead of revenue to staff new lines; and a tax provision on the shrinking pre-tax number. Together, they compressed PAT margin from 17.2% (H1 FY26) to 15.8% (Q2 FY27). A 160 bp loss in a single quarter — entirely structural, not competitive.
Highest-ever quarterly revenue ₹187.8 Cr standalone; 31.6% YoY growth
Consolidated ₹190.9 Cr; YoY +31.1% — nearly identical to claimed 31.6%
Supported
EBITDA ₹70.4 Cr grew 37.1% YoY; margin 37.5%
Consolidated EBITDA margin 37.9% — well above stated 37.5% and guidance band
Supported (beats own claim)
PAT ₹30.8 Cr, margin 16.4%, profit stable sequentially
PAT ₹30.9 Cr at 15.8% margin; down 5.2% YoY and down 12% QoQ from Q1 ₹35.2 Cr
Contradicted
H1 PAT grew 6.6% YoY showing profit resilience
H1 growth 6.6% true, but Q2 alone shows -5.2% YoY; growth weighted by softer Q1
Overstated
Capacity setup complete; 80% of expansion stabilized in Q1
44,800 sq m GE Vernova facility commissioned Sep 2026; now production-ready; ramp begins Q3
Supported (capex on track)
Order book ₹6,500+ Cr; multi-year rolling contracts with deep visibility
Order book cited; 5–7 year rolling contract model; anchored by BHEL (₹52.68 Cr annually, extended 2030) and Baker Hughes (extended 2030)
Supported
What changed on this call
Margin guidance reaffirmed but profit guidance withdrawn. Management maintained 25%+ long-term revenue growth and 32–35% EBITDA margin band (delivered 37.9%, well above). But when asked for FY28 net income targets, MD Rakesh Chopdar deflected: 'I do not think, maybe next quarter I can update you exactly what would be the range.' This is de facto withdrawal of specific profit guidance — a first. Cost lag is now acknowledged as a multi-quarter phenomenon, not a one-quarter anomaly. New: the ₹1,300+ Cr ARR target by end FY28 — announced without fanfare but represents 1.7x growth from current ₹760 Cr run rate, higher than historical 25%+ guidance messaging and implicit acknowledgement of an acceleration phase ahead.
The bull-bear ledger
Record ₹190.9 Cr revenue, +31.1% YoY; H1 growth 29.3%, ahead of 25% guidance
EBITDA margin 37.9%, 150 bps expansion YoY, well above 32–35% guidance band
₹6,500 Cr order book on 5–7 year rolling contracts; BHEL extended to 2030; supply chain locked in
44,800 sq m GE Vernova facility live Sep 2026; 6 customer-dedicated lean lines; production-ready for Q3 ramp
Multiple OEM qualifications in final stages (Rolls-Royce 2 engines, Pratt & Whitney, Safran, GTRE); FY28 H1 aero engine revenue begins
PAT down 5.2% YoY despite 31% revenue growth — structural red flag on earnings quality
Net profit margin fell 160 bps YoY; profit guidance explicitly not quantified
Operating cash flow -₹45.8 Cr (H1); inventory bloat ₹425 Cr (+₹98 Cr), receivables ₹402 Cr (+₹92 Cr); Q4 stabilization timing uncertain
FII ownership fell 3.45 percentage points QoQ (16.15% Q1 FY26 → 12.70% Q2 FY27); institutional skepticism evident
Stock down 21.4% from all-time high ₹3,126 to ₹2,456; below 20-day and 50-day moving averages
88% export exposure; geopolitical headwinds (US sanctions on Iran, EU trade shifts) could disrupt demand
Customer concentration risk: top customers unnamed; dedicated facilities create switching-cost lock-in but single-customer loss strands assets
Street positioning: why FII is selling
The market has priced in the profit miss. FII ownership collapsed 3.45 percentage points from Q1 FY26 (16.15%) to Q2 FY27 (12.70%), signalling institutional flight. The stock has been marked down 21% from its all-time high of ₹3,126, now trading at ₹2,456 — below its 20-day moving average (₹2,533) and 50-day MA (₹2,706), though above the 200-day MA (₹2,197). The RSI sits at 40.8, neutral. The selloff is logical: profit declined while capex burn persisted, cash conversion cycle extended, and management punted on earnings visibility. What the market is asking: Can Azad actually hit H2 acceleration and Q4 cash inflection, or is this a longer cycle than guided? FII's exit into weakness hints they are unsure.
Qualification timeline slippage
HighRolls-Royce (2 engines), Pratt & Whitney, Safran, GTRE each typically carry 3–6 month buffer risks. Management says 'almost done' but no firm dates. Even a 3-month delay postpones ₹50–100 Cr revenue inflection and extends payback by one quarter.
Cash conversion cycle extension
HighH1 OCF -₹45.8 Cr with inventory +₹98 Cr and receivables +₹92 Cr. CFO expects Q4 swing, but macro headwinds (demand slowdown, customer payment delays) could delay the turnaround. Working capital intensity could persist into FY28.
PAT margin recovery uncertainty
HighProfit fell 5.2% despite 31% revenue growth. Depreciation, interest, and labour costs will rise further as new facilities ramp. Management provided no timeline for margin recovery to 17%+ levels. If fixed costs don't absorb as capacity utilizes, PAT could remain under pressure through FY28.
Customer and export concentration
Medium88% export (primarily Mitsubishi, GE, Rolls-Royce, Safran, Baker Hughes). Top customers unnamed. Dedicated facilities create switching-cost lock-in but also mean facility-customer pairing: single-customer loss = stranded asset of ₹100+ Cr.
Interest cost rising, leverage rising
MediumFinance cost +45% YoY to ₹12.2 Cr. Total debt ₹1.07 Cr; debt-to-equity 1.6x, debt-to-EBITDA 1.5x (healthy but rising). If capex extends or interest rates spike, cost pressure persists and PAT margin recovery slips.
Geopolitical disruption (sanctions, trade policy)
MediumA&D segment (₹31.7 Cr, 17% of revenue) dependent on Rolls-Royce (UK), Safran (France), Pratt & Whitney (US). US sanctions on Iran reduce oil/gas engine demand. China competition in defence indigenization. Policy shifts could disrupt qualification timelines and demand.
1 · Q3 ramp acceleration (Oct–Dec 2026)
GE Vernova and Mitsubishi dedicated lines must convert installed capacity into revenue. Watch for: (a) revenue growth acceleration vs. Q2 (guidance hints H2 will be stronger), (b) actual utilization rates on new lines (capacity installed ≠ revenue realized), and (c) first aero engine airfoil shipments to Rolls-Royce or Pratt & Whitney. Miss here extends pain into FY28.
2 · Q4 cash inflection (Jan–Mar 2027)
Operating cash flow must swing from -₹45.8 Cr (H1) to positive. CFO flagged this explicitly ('as throughput converts to revenue, inventory turns to receivable, then to cash'). This is the proof point for the capex thesis. If Q4 OCF is still negative or weakly positive, working capital management is worse than assumed, and FY28 earnings recovery becomes suspect.
3 · FY28 H1 qualifications unlocking (Apr–Sep 2027)
Rolls-Royce aero engine airfoil production revenue must begin. Pratt & Whitney and Safran qualifications must complete. Management flagged 'very soon' but gave no calendar dates. This is the ₹200–300 Cr revenue inflection that justifies the ₹1,300 Cr ARR target. Delays or failures here invalidate the long-term thesis. Track the press releases and earnings call tone for firmness of timelines.
Azad is executing a disciplined capex build, not stumbling. The paradox — record revenue and EBITDA margin strength paired with falling profit — is entirely structural: depreciation, interest, and manpower costs are front-loaded by design. The market's 21% pullback and FII exodus reflect legitimate timing risk, not fundamental failure. Azad is a Hold for investors already long, not a buy into strength.
The single number to track is operating cash flow. If H1's -₹45.8 Cr turns positive in Q4 as guided, the thesis is intact and FY28 earnings recovery is probable. If it doesn't, the ₹1,300 Cr ARR capacity target becomes optimistic and payback extends. Watch the cash. That is where the capex story either validates or ruptures.